The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: Analysis based on routine therapeutic drug monitoring data

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 115-119

  Sriboonruang, Tatta ^a   Panomvana, Duangchit ^a   Chamchitchun, Santichai ^b   Silpakit, Orawan ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Srithanya Hospital   (Thailand)

Author keywords

clearance; dose dependent pharmacokinetics; plasma concentration; sustained release formulation; valproate

Indexed keywords

VALPROIC ACID;

ADULT; ANALYZER; ARTICLE; CENTRIFUGATION; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BINDING; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; STUDENT T TEST; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; VALPROIC ACID; YOUNG ADULT;

EID: 78651271813     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318203b405     Document Type: Article

References (29)

1. Anonymous. Valproic acid and sodium valproate approved for use in epilepsy. FDA Drug Bull. 1978;8(2):14-15.
2. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37(suppl 2):5-16.
3. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-694.
4. Davis LL, Ryan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol. 2000;20(suppl 1):1SY17S.
5. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992;12(suppl 1):42SY52S.
6. Adamou M, Puchalska S, Plummer W, et al. Valproate in the treatment of PTSD: systematic review and meta analysis. Curr Med Res Opin. 2007;23(6):1285-1291.
7. Haddad PM, Das A, Ashfaq M, et al. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol. 2009;5(5):539-551.
8. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther. 1977;21(6):736-743.
9. Albright PS, Bruni J, Suria D. Pharmacokinetics of enteric-coated valproic acid. Ther Drug Monit. 1984;6(1):21-23.
10. Yamatogi Y, Yoshinaga H, Oka E, et al. Pharmacokinetics of slow-release preparations of sodium valproate. Psychiatry Clin Neurosci. 1995;49(5-6):309- 310.
11. Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199-216.
12. Pinder RM, Brogden RN, Speight TM, et al. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1977;13(2):81-123.
13. Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed? Clin Neuropharmacol. 2006;29(6):350-360.
14. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153(6):765-770.
15. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47(2):332-372.
16. Bourgeois BFD. Chapter 86. Valproic acid. Clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia, PA: Lippincott William & Wilkins; 2002:807-817.
17. Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31(4):205-216.
18. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37(suppl 2):25-42.
19. Shargel L, Yu A, eds. Applied Biopharmaceutics and Pharmacokinetics. 4th ed. Norwalk, CT: Appleton & Lange; 1999.
20. Bowdle AT, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther. 1980;28(4):486-492.
21. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, et al. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther. 1993;18(3): 191-197.
22. Felix S, Sproule BA, Hardy BG, et al. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J Clin Psychopharmacol. 2003;23(5):471-478.
23. Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005;28(2):96-101.
24. Gidal BE, Ramsay E, Howes J, et al. Evaluation of the potential pharmacokinetic interaction between sodium valproate and the investigational antiepileptic drug talampanel. Neurology. 2005;64(6):A189-A189.
25. Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther. 2005;30:417-421.
26. Eyer F, Felgenhauer N, Gempel K, et al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005;25(4):376-380.
27. Gidal BE, Pitterle ME, Spencer NW, et al. Relationship between valproic acid dosage, plasma-concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Ther. 1995;20(4):215-219.
28. Herngren L, Nergardh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J Neurol. 1988;235(8):491-495.
29. Winter ME. Valproic acid. In: Winter ME, ed. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia, PA: Lippincott William & Wilkins; 2004:438-445.